MannKind Corp (MNKD):企業の財務・戦略的SWOT分析

◆英語タイトル:MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH44250FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

MannKind Corp (MNKD) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. It consists of a dry powder formulation of human insulin delivered from small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. The company has manufacturing facility in Danbury, Connecticut and sells product to wholesale distributors and specialty pharmacies in the US. MannKind is headquartered in Westlake Village, California, the US.

MannKind Corp Key Recent Developments

Mar 10,2021: MannKind Corporation to Participate in Oppenheimer’s 31st Annual Healthcare Conference
Feb 25,2021: MannKind reports 2020 fourth quarter and full year financial results
Feb 18,2021: MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
Dec 10,2020: James S. Shannon transitions to chairman of the board of directors for MannKind
Dec 01,2020: MannKind and MidCap amend credit facility

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
MannKind Corp – Key Facts
MannKind Corp – Key Employees
MannKind Corp – Key Employee Biographies
MannKind Corp – Major Products and Services
MannKind Corp – History
MannKind Corp – Company Statement
MannKind Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
MannKind Corp – Business Description
Business Segment: Collaborations and Services
Overview
Performance
Business Segment: Commercial Product Sales
Overview
Performance
R&D Overview
MannKind Corp – Corporate Strategy
MannKind Corp – SWOT Analysis
SWOT Analysis – Overview
MannKind Corp – Strengths
MannKind Corp – Weaknesses
MannKind Corp – Opportunities
MannKind Corp – Threats
MannKind Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MannKind Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 10, 2021: MannKind Corporation to Participate in Oppenheimer’s 31st Annual Healthcare Conference
Feb 25, 2021: MannKind reports 2020 fourth quarter and full year financial results
Feb 18, 2021: MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
Dec 10, 2020: James S. Shannon transitions to chairman of the board of directors for MannKind
Dec 01, 2020: MannKind and MidCap amend credit facility
Nov 30, 2020: Sabrina Kay appointed to MannKind Board of Directors
Nov 04, 2020: MannKind reports 2020 third quarter financial results
Aug 31, 2020: Kevin Kaiserman joins MannKind as Vice President, Medical Affairs and Safety
Aug 05, 2020: MannKind reports 2020 second quarter financial results
Jul 20, 2020: Alejandro Galindo joins MannKind as Chief Commercial Officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
MannKind Corp, Key Facts
MannKind Corp, Key Employees
MannKind Corp, Key Employee Biographies
MannKind Corp, Major Products and Services
MannKind Corp, History
MannKind Corp, Other Locations
MannKind Corp, Subsidiaries
MannKind Corp, Key Competitors
MannKind Corp, Ratios based on current share price
MannKind Corp, Annual Ratios
MannKind Corp, Annual Ratios (Cont...1)
MannKind Corp, Annual Ratios (Cont...2)
MannKind Corp, Interim Ratios
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
MannKind Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[MannKind Corp (MNKD):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Citizens Financial Corp.:企業の戦略・SWOT・財務情報
    Citizens Financial Corp. - Strategy, SWOT and Corporate Finance Report Summary Citizens Financial Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sunshine Biopharma Inc (SBFM):企業の財務・戦略的SWOT分析
    Summary Sunshine BioPharma Inc (Sunshine BioPharma), a subsidiary of Advanomics Corp is a pharmaceutical company that offers research, development and commercialization of drugs for treating cancer disease. The company provides generic and proprietary drugs for the treatment of cancer and other acut …
  • OSE Immunotherapeutics (OSE):製薬・医療:M&Aディール及び事業提携情報
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • Kaiser Permanente:企業の戦略・SWOT・財務情報
    Kaiser Permanente - Strategy, SWOT and Corporate Finance Report Summary Kaiser Permanente - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • VistaGen Therapeutics Inc (VTGN):企業の財務・戦略的SWOT分析
    Summary VistaGen Therapeutics Inc (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate recep …
  • Medical University of Vienna-製薬・医療分野:企業M&A・提携分析
    Summary Medical University of Vienna (MUV) is a medical research institute that offers educational services. The institute provides research and education services in the field of medical science. Its research services include project submission, clinical and preclinical studies, research funding, b …
  • MedinCell SA (MEDCL):製薬・医療:M&Aディール及び事業提携情報
    Summary MedinCell SA (MedinCell) is a developer of therapeutic solutions for the healthcare market. The company develops and commercializes BEPO, a technology based on custom proprietary copolymers and a biocompatible solvent for long acting injectables. Its BEPO provides a controlled release of the …
  • Wincor Nixdorf AG:企業の戦略・SWOT・財務情報
    Wincor Nixdorf AG - Strategy, SWOT and Corporate Finance Report Summary Wincor Nixdorf AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • REC Silicon ASA (REC):電力:M&Aディール及び事業提携情報
    Summary REC Silicon ASA (REC Silicon), formerly Renewable Energy Corporation ASA, is a producer of advanced silicon materials, and delivers high-purity polysilicon and silicon gas. Its products find application in the solar and electronics industries in the production of solar panels, flat panel dis …
  • Keepmoat Ltd:企業の戦略的SWOT分析
    Keepmoat Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Mitsubishi Motors Corporation:企業の戦略・SWOT・財務情報
    Mitsubishi Motors Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Motors Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Safran SA (SAF):企業の財務・戦略的SWOT分析
    Safran SA (SAF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Mckesson Europe AG (CLS1):製薬・医療:M&Aディール及び事業提携情報
    Summary Mckesson Europe AG (Mckesson Europe), formerly known as Celesio AG, is a provider of logistics and services to healthcare and pharmaceutical sectors across Europe. The company is involved in providing distribution solution to its wholesale, institutional and retail customers and delivering p …
  • Intra-Cellular Therapies Inc (ITCI):企業の財務・戦略的SWOT分析
    Summary Intra-Cellular Therapies Inc (ITI) is a novel drug manufacturer. The company offers product platform such as ITCI Pipeline that includes lumateperone, ITI-007 platform, PDE inhibitor platform and drug discovery platform. The company’s lead product candidate ITI-007-lumateperone is to treat s …
  • Royal Mail plc:企業の戦略・SWOT・財務分析
    Royal Mail plc - Strategy, SWOT and Corporate Finance Report Summary Royal Mail plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Policolor SA:企業の戦略的SWOT分析
    Policolor SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • PT. Millennium Pharmacon International TBK (SDPC):企業の財務・戦略的SWOT分析
    PT. Millennium Pharmacon International TBK (SDPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Petroleo Brasileiro SA (PETR4)-石油・ガス分野:企業M&A・提携分析
    Summary Petroleo Brasileiro S.A. (Petrobras) is an integrated oil and gas company. Its major businesses include exploration and production, refining, marketing , trade and transportation of oil and gas. The company also conducts biofuel, petrochemical, natural gas, electricity and chemical-gas busin …
  • Crescita Therapeutics Inc (CTX):企業の財務・戦略的SWOT分析
    Summary Crescita Therapeutics Inc (Crescita Therapeutics) is a commercial dermatology company that offers prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. The company’s products comprise Pliaglis, Alyria, Laboratoire Dr Renaud, Pro-Derm, Premi …
  • Gulfport Energy Corp (GPOR):企業の財務・戦略的SWOT分析
    Gulfport Energy Corp (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆